GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,990 DKK | -0.65% |
|
-0.70% | -7.66% |
| 03/05 | GENMAB : A good start to 2024; guidance unchanged |  |
| 03/05 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
Presenter SpeechKeyur Parekh (Analysts)Good afternoon, and thank you all for joining us. My na...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,990
DKK
Average target price
2,470
DKK
Spread / Average Target
+24.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.66% | 1.87TCr | |
| +5.66% | 11TCr | |
| +11.23% | 11TCr | |
| -0.38% | 2.23TCr | |
| -12.15% | 2.21TCr | |
| -36.52% | 1.76TCr | |
| -10.09% | 1.69TCr | |
| +3.33% | 1.38TCr | |
| +36.58% | 1.25TCr | |
| +288.77% | 812.02Cr |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-12-2018 04